Gene therapy for sickle cell: how young is too young for a functional cure?

Sickle cell disease, a genetic blood disorder affecting haemoglobin, leads to rigid, sickle-shaped red blood cells that obstruct blood flow, causing severe pain, anaemia, and organ damage. Standard treatments manage symptoms and complications, but do not address the underlying genetic defect. For decades, allogeneic hematopoietic stem cell transplantation (HSCT) has been the only curative option, but it carries substantial risks, including graft-versus-host disease, and requires a matched donor, which is often unavailable. This leaves a significant unmet need for a broadly accessible, curative therapy, especially for children who face a lifetime of complications.

The newly approved gene therapy, exagamglogene autotemcel (exa-cel), targets the genetic root of sickle cell disease. It involves collecting a patient's own hematopoietic stem cells, modifying them ex vivo to increase fetal haemoglobin production, and then reinfusing them after myeloablative conditioning. This approach aims to provide a functional cure by enabling the body to produce red blood cells that resist sickling. The FDA's decision specifically covers patients aged 12 years and older with severe sickle cell disease who have a history of recurrent vaso-occlusive crises (VOCs).

The mechanism and the evidence

Exa-cel works by editing the BCL11A gene in the patient's own stem cells. This editing reactivates the production of fetal haemoglobin (HbF), a form of haemoglobin naturally produced during gestation that does not sickle. Increasing HbF levels dilutes the concentration of sickle haemoglobin (HbS), preventing red blood cells from deforming and blocking blood vessels. The therapy uses CRISPR/Cas9 technology to achieve this precise genetic modification.

Clinical trials, including the CLIMB-111 and CLIMB-121 studies, evaluated the safety and efficacy of exa-cel. These open-label, single-arm studies enrolled patients with severe sickle cell disease. The primary endpoint was freedom from severe vaso-occlusive crises (VOCs) for at least 12 consecutive months after infusion. In CLIMB-111, 36 of 38 patients (94.7%) achieved this primary endpoint, remaining free of severe VOCs for at least one year. The remaining two patients experienced a reduction in severe VOCs of 90% and 75%, respectively. All 38 patients maintained normal or near-normal haemoglobin levels, with a mean total haemoglobin of 13.2 g/dL at 12 months post-infusion.

Patients also showed sustained production of anti-sickling haemoglobin. The mean percentage of fetal haemoglobin (HbF) among total haemoglobin was 39.8% at 12 months, a level sufficient to prevent sickling. This sustained HbF production translated into a dramatic reduction in hospitalisations for VOCs. Before treatment, patients experienced a median of 3.9 severe VOCs per year. After treatment, the median number of severe VOCs was 0 per year, a clinically meaningful outcome for patients and their families.

Safety profile and practical considerations

The safety profile of exa-cel largely reflects the myeloablative conditioning regimen required before stem cell infusion. Common adverse events included mucositis, febrile neutropenia, and other cytopenias, consistent with busulfan conditioning. These events are transient and manageable with supportive care. No cases of graft-versus-host disease occurred, as the therapy uses autologous cells. The long-term safety of gene-edited cells remains an ongoing area of surveillance, but initial data show no unexpected toxicities or clonal abnormalities.

The logistical complexity of gene therapy is an obvious caveat. The process involves apheresis, gene modification in a specialised facility, myeloablative conditioning, and reinfusion, requiring significant coordination and patient support. Access to these highly specialised treatment centres will be a critical determinant of uptake. The cost of gene therapy is also substantial, raising questions about equitable access and healthcare system sustainability. Still, for a disease with such high morbidity and mortality, a functional cure offers immense value.

The FDA's approval of exa-cel for children as young as 12 months represents a significant expansion of treatment options. This younger age group is particularly vulnerable to the early onset of organ damage from sickle cell disease, making early intervention critical. The Oxford Handbook of Paediatrics provides a comprehensive overview of managing such complex conditions in children. The therapy was tested only in patients with severe disease; whether benefits extend to those with less severe phenotypes remains unclear, and further research will be necessary to define the full spectrum of eligible patients.